Pediatric Stem Cell & CAR-T Cellular Therapy Scrubber
Cellular immunotherapy and pediatric bone marrow transplantation involve extraordinary reimbursement stakes: a single autologous CAR-T dose (tisagenlecleucel, Q2042) exceeds $475,000. Commercial prior-authorization pitfalls, routine clearinghouse bundling of restaging intrathecal chemo (96450) into bone marrow biopsy (38222), and payer downcoding of post-infusion Cytokine Release Syndrome (CRS) critical care trigger catastrophic losses. Audit your cellular oncology dossiers for bulletproof compliance.
Pediatric Stem Cell & CAR-T Cellular Therapy Scrubber
Audit FDA-approved CAR-T infusions (0540T / Q2042), defend severe Cytokine Release Syndrome (CRS) critical care downcodings (99291), and prevent bundling of intrathecal restaging (96450) and bone marrow biopsies (38222).
Statutory & Prior-Auth Analysis
All CAR-T procedural codes (0540T), biologic product authorizations (Q2042), distinct restaging procedures (96450-59 / 38222), and ASTCT critical care intervals satisfy federal and commercial compliance gates.
Authority: CMS NCD 110.24; FACT (Foundation for the Accreditation of Cellular Therapy) Standards
| CPT / HCPCS | Procedure / Biologic Description | Modifier | Work RVU | Allowable | Clinical Rule & Note |
|---|---|---|---|---|---|
| 0540T | Chimeric antigen receptor T-cell (CAR-T) therapy; autologous administration (infusion) | None | 18.2 | $1,850 | Physician direct supervision of autologous CAR-T cell infusion. |
| Q2042 | Tisagenlecleucel, up to 250 million CAR-positive viable T cells (Kymriah) | None | 0 | $475,000 | High-cost biologic product approved under authorized commercial single-case agreement. |
| 96450 | Chemotherapy administration into central nervous system (Intrathecal methotrexate/cytarabine) | -59 / -XS | 5.2 | $380 | Modifier 59/XS appended to distinguish lumbar puncture from iliac crest aspiration. |
| 38222 | Diagnostic bone marrow biopsy and aspiration (Pediatric leukemia restaging) | None | 6.8 | $490 | Combined bone marrow biopsy and aspiration; bilateral or unilateral iliac crest. |
| 99291 | Critical care, evaluation and management; first 30-74 minutes (ASTCT Grade 3 CRS / ICANS) | -25 | 12.8 | $420 | Documented life-threatening hemodynamic instability and tocilizumab infusion monitoring. |
ISA*00* *00* *ZZ*SUBMITTER1 *ZZ*PAYER001 *260905*1300*^*00501*000000001*0*T*:~ GS*HC*SUBMITTER1*PAYER001*20260905*1300*1*X*005010X222A1~ ST*837*0001*005010X222A1~ BHT*0019*00*CELL9028*20260905*1300*CH~ NM1*85*2*PEDIATRIC CELLULAR ONCOLOGY GROUP*****XX*1762534910~ HL*1**20*1~ HL*2*1*22*0~ NM1*IL*1*PEDIATRIC*PATIENT*****MI*PEDS994821~ CLM*CELL20260905*478140***11:B:1*Y*A*Y*Y~ HI*ABK:C91.00*ABF:T86.5*ABF:R65.21~ LX*1~ SV1*HC:0540T*1850*UN*1***1~ DTP*472*D8*20260905~ LX*2~ SV1*HC:Q2042*475000*UN*1***1~ DTP*472*D8*20260905~ LX*3~ SV1*HC:96450:59XS*380*UN*1***1~ DTP*472*D8*20260905~ LX*4~ SV1*HC:38222*490*UN*1***1~ DTP*472*D8*20260905~ LX*5~ SV1*HC:99291:25*420*UN*1***1~ DTP*472*D8*20260905~ SE*26*0001~ GE*1*1~ IEA*1*000000001~
Turn these Pediatric Cellular Therapy & Oncology RCM insights into recovered cash
Navigating high-cost CAR-T prior authorization requirements, bone marrow transplant unbundling denials, or intensive CRS critical care appeals? Aethera's specialized pediatric cellular therapy coding experts protect your program. Let our senior AAPC-certified billing team audit 50 of your active claims or past denials — completely free, with guaranteed under-48-hour findings.
Test our scrub rules and appeal workflow on 50 real claims. Zero commitment, no credit card required.
Upload your aging report for instant benchmark comparisons against MGMA standards and recoverable cash projections.